Mouse Study Shows Tirzepatide Slows Growth of Obesity-Related Breast Cancer
A groundbreaking mouse study presented at ENDO 2025 shows that tirzepatide, an anti-obesity medication, can slow the growth of breast cancer linked to obesity. These findings may pave the way for new cancer treatments targeting obesity-related pathways.
A recent study presented at ENDO 2025, the annual meeting of the Endocrine Society in San Francisco, has revealed promising findings on the effects of tirzepatide, an anti-obesity medication, on breast cancer in a mouse model. Known commercially as Mounjaro for diabetes and Zepbound for obesity, tirzepatide was found to significantly reduce breast tumor growth in mice that were made obese through a high-fat diet.
In this study, 16 nine-week-old C57BL/6 mice were fed a diet consisting of 40% fat to induce obesity. At 32 weeks, the obese mice received injections of tirzepatide or a placebo every other day for a period of 16 weeks, with tumor sizes measured twice weekly. The mice treated with tirzepatide experienced a weight and fat reduction of approximately 20%, mainly due to loss of adipose tissue, with a significant decrease in fat depot weights compared to untreated controls.
The key finding was that tumor volume was markedly smaller in the mice receiving tirzepatide. At the study’s conclusion, tumor size was closely linked to body weight, total adipose tissue, and liver fat content. These results suggest that tirzepatide, beyond its role in weight management, might have a beneficial impact on breast cancer outcomes, especially in cases linked to obesity.
"While these findings are preliminary, they indicate that anti-obesity drugs like tirzepatide may help reduce breast cancer risk or improve treatment results," explained study author Amanda Kucinskas, a Ph.D. candidate at the University of Michigan. The ongoing research aims to distinguish the effects of weight loss itself from those directly related to the tumor, collaborating with experts at the University of North Carolina.
Obesity is a known risk factor for poorer breast cancer prognosis, with weight loss often leading to better outcomes. However, traditional weight management methods face many challenges. The study highlights tirzepatide’s dual potential for weight reduction and cancer treatment, opening new avenues for research in obesity-related cancer therapies.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
'Creeping fat' Exacerbates Crohn’s Disease, New Study Reveals
New research reveals that creeping fat actively worsens Crohn's disease by promoting intestinal scarring, offering new avenues for treatment beyond anti-inflammatory drugs.
Impact of Water Fluoridation Cessation on Dental Health in Towns
Towns halting water fluoridation face increased risks of dental cavities. Understanding the importance and safety of fluoride in preventing oral health issues is essential for communities. Learn how water fluoridation supports dental health and the implications of its removal.
Innovative Induction of Labor Program Enhances Maternal Health Outcomes
A new induction of labor initiative at Western Health has successfully reduced rates and improved women’s understanding and experience, highlighting the importance of guidelines and dedicated care roles for safer maternal outcomes.
Assisted Dying: Key Challenges and Practical Considerations Before Legislation
A comprehensive look at the key practical challenges of legalizing assisted dying in England and Wales, including medication safety, workforce capacity, and legal considerations.